Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Caution still advised despite ever-improving drugs

30.11.2012
World AIDS Day: Results of Swiss HIV Cohort Study

Combination therapies for AIDS are becoming increasingly effective, but they cannot protect against other sexually transmitted illnesses. It is unsafe for patients taking antiretroviral drugs to stop using condoms. This is one of the findings of research conducted in the Swiss HIV Cohort Study, which is supported by the SNSF.

Drugs for HIV, the virus causing AIDS, have existed for more than two decades. Therapies have been continually refined and the standard approach in the West is now a combination therapy involving various antiretroviral substances. The rationale behind this idea is that the constantly changing virus finds it harder to develop resistances against three or more drugs administered simultaneously.

Less resistance to new drugs
At the beginning of the year, Huldrych Günthard (University Hospital Zurich) and his colleagues from the Swiss HIV Cohort Study showed (*) that new combination therapies are better at keeping viruses in check than the therapies used ten years ago. For the older therapies, resistant viruses developed on average 2.6 times per 100 patient-years (i.e. 100 patients over the course of one year, 50 over the course of two years) while resistance to the newer therapies developed only 1.5–1.9 times. Researchers believe that this improvement is not only the result of greater drug effectiveness – patients also tend to take the drugs more regularly because they have less side-effects.
Dramatic spread of hepatitis C
The continual improvement of combination therapies reduces the risk of HIV transmission. Recently published results of the Swiss HIV Cohort Study (**) suggest that this leads to a false sense of security in certain patients. Figures show that hepatitis C has spread rapidly among HIV-positive gay men during the last few years. While the rate of infection among heterosexuals has remained low (on average 0.4 infections per 100 patient-years), it has risen drastically among homosexuals: 4.1 persons are infected per 100 patient-years. This rate is 18 times higher than the one recorded in 1998.

Researchers point to the inconsistent use of condoms as the greatest risk factor. While the fear of AIDS has understandably diminished, there may be a tendency now to neglect other sexually transmitted illnesses. "Caution is still called for," says Günthard.

(*) von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Günthard HF; Swiss HIV Cohort Study (2012). Incidence of HIV-1 drug resistance among antiretroviral treatment-naive individuals starting modern therapy combinations. Clin Infect Dis. 54:131-40

(**) Wandeler G, Gsponer T, Bregenzer A, Günthard HF, Clerc O, Calmy A, Stöckle M, Bernasconi E, Furrer H, Rauch A; Swiss HIV Cohort Study (2012). Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. Clin Infect Dis. 55:1408-1416

(Available as a PDF from the SNSF; e-mail: com@snf.ch)

The Swiss HIV Cohort Study
Established in 1988, the Cohort Study aims to generate knowledge about HIV infection and AIDS as well as to improve the care given to patients. All Swiss hospitals specialising in HIV (Basel, Berne, Geneva, Lausanne, Lugano, St. Gallen and Zurich) have collected and analysed data from over 16,000 HIV-positive persons. Currently, more than 8,400 persons are taking part in the Swiss HIV Cohort Study. Almost a third of them are women.
Contact
Prof. Dr. med. Huldrych Günthard
Klinik für Infektionskrankheiten und Spitalhygiene
Universitätsspital Zürich
Rämistrasse 100
8091 Zürich
Tel.: +41 (0)44 255 34 50
E-mail: huldrych.guenthard@usz.ch

Abteilung Kommunikation | idw
Further information:
http://www.snsf.ch
http://www.shcs.ch/

Further reports about: Aids HIV HIV Cohort Study HIV-positive Hepatitis C SNSF

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>